Guardant Health (GH) announced that its Shield multi-cancer detection test has been granted Breakthrough Device designation from the FDA. The Shield MCD test is a methylation-based blood test for the multi-cancer screening of multiple cancer types including bladder, colorectal, esophageal, gastric, liver, lung, ovarian and pancreas cancer in individuals aged 45 or older who are at typical average risk for cancer.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health’s Strategic Advancements and Innovative Growth Drive Buy Rating
- Guardant Health’s Shield Test Gains Momentum with NCCN Guideline Inclusion, Driving Growth Prospects
- Cathie Wood’s ARK Investment buys 158.7K shares of Guardant Health today
- Guardant Health announces NCCN has included Shield blood test in CRC guidelines
- Guardant Health announces results of Phase III SERENA-6 trial